However, in infants born to women with T2D treated with second-line ADM, we did not observe a greater risk of MCMs after periconceptional exposure to sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, or SGLT2 inhibitors compared with insulin. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.